Protocol summary of a randomized controlled phase III trial for confirming the superiority of local radiotherapy for prostate cancer patients with high-volume metastasis sensitive to hormonal therapy: the JCOG2011 (HimeRT study).
Naoki Terada, Keiji Nihei, Rihito Aizawa, Shintaro Narita, Takahiro Kojima, Masaki Shiota, Shusuke Akamatsu, Takahiro Kimura, Takahiro Inoue, Mikio Sugimoto, Yuta Sekino, Keita Sasaki, Taro Shibata, Haruhiko Fukuda, Hiroyuki Nishiyama, Hiroshi Kitamura, Takashi Mizowaki, Urological Oncology Study Group (UOSG) and the Radiation Therapy Study Group (RTSG) of the Japan Clinical Oncology Group (JCOG) Kamoto Toshiyuki
Jpn J Clin Oncol 56(1) 104-109
摘要
摘要
Local therapy is not considered a standard treatment option for patients with high-volume metastatic prostate cancer. Our research group's previous retrospective study indicated potential benefits of local radiotherapy (LRT) for some high-volume metastatic prostate cancer patients, but prospective studies have yet to confirm these findings. We have thus planned a multicenter, open-label, randomized controlled phase III trial to confirm the efficacy of adding LRT to systemic hormonal therapy with androgen deprivation therapy plus an androgen receptor pathway inhibitor in a population of high-volume metastatic prostate cancer patients for whom the hormonal therapy is effective for 6 months. The primary endpoint is failure-free survival, defined as the time from randomization to prostate-specific antigen progression, radiological progression, clinical progression, or death from any cause. We aim to enroll 360 patients from 56 institutions over a 4-year period. This trial is registered at the Japan Registry of Clinical Trials (study no. jRCT1031220676).
KM 提取结果
0 个 Figure · 0 个 KM 面板